Clinical bottom line
Notalgia paresthetica (NP) is a chronic neuropathic pruritic condition characterized by localized itching and dysesthesia typically affecting the upper back. Recent systematic reviews highlight a range of emerging systemic treatment options with modest efficacy and varying safety profiles. While no definitive systemic therapy has yet achieved broad consensus, several agents—including neuropathic pain modulators and novel neuroactive drugs—show promise in alleviating symptoms. Clinicians should weigh current evidence cautiously, individualize treatment, and remain alert to ongoing research developments.
What the evidence shows
Notalgia paresthetica is understood as a sensory neuropathy involving cutaneous nerve entrapment or irritation, leading to chronic localized pruritus without primary skin lesions (Marcusson et al., 1990; Šitum et al., 2018). The pathophysiology appears to involve pruritic-specific neural mechanisms distinct from pain or thermal sensory pathways (Chu et al., 2023).
A recent systematic review by Bai Jia Qi Adam et al. (2025) synthesized available clinical trial and observational data on systemic treatments for NP. The review identified several candidate agents:
- Gabapentinoids (gabapentin, pregabalin): These neuropathic pain modulators demonstrated modest reductions in pruritus intensity in small open-label studies and case series, with tolerability generally acceptable but limited by sedation and dizziness.
- Duloxetine and other serotonin-norepinephrine reuptake inhibitors (SNRIs): Preliminary evidence suggests potential benefit through central neuromodulation, though data remain sparse and largely anecdotal.
- Capsaicin systemic analogues and neurokinin-1 receptor antagonists: These novel agents are under early investigation; current evidence is insufficient to support routine use.
- Other systemic agents: Limited reports exist for anticonvulsants, antidepressants, and muscle relaxants, but robust efficacy data are lacking.
Nierengarten et al. (2023) reported on a new neuroactive agent trialed in NP patients, showing modest symptom improvement but accompanied by side effects such as nausea and fatigue, underscoring the need for careful risk-benefit assessment.
Overall, the evidence base is constrained by small sample sizes, heterogeneous study designs, and a paucity of randomized controlled trials. Most data derive from case reports, retrospective series, or small open-label studies (Bai Jia Qi Adam et al., 2025).
Caveats and uncertainty
The clinical heterogeneity of NP and its neuropathic basis complicate treatment evaluation. Sensory testing confirms that itch mechanisms in NP differ from pain and thermal pathways, suggesting that conventional antipruritic or analgesic treatments may not be uniformly effective (Chu et al., 2023).
No systemic treatment has yet demonstrated consistent, large effect sizes in well-powered randomized trials. Adverse effects, particularly central nervous system symptoms, limit tolerability for some agents. The lack of standardized outcome measures and placebo-controlled data further restricts definitive conclusions.
Moreover, NP’s chronicity and often refractory nature mean that symptom control rather than cure is the realistic therapeutic goal. The potential for spontaneous symptom fluctuation also complicates assessment of treatment efficacy.
How this may change practice
Clinicians managing NP should recognize it as a neuropathic pruritus syndrome warranting a multimodal approach. Systemic therapies may be considered for patients with moderate to severe symptoms refractory to topical or physical modalities.
Gabapentinoids currently represent the most evidence-supported systemic option, albeit with modest benefit and side effect considerations. Emerging neuroactive agents may expand therapeutic choices in the near future but require further validation.
Careful patient selection, counseling on realistic expectations, and monitoring for adverse effects are essential. Incorporating sensory testing and neuropathic itch assessment tools may aid in tailoring therapy.
Ongoing research and clinical trials are needed to establish standardized systemic treatment protocols and to explore novel mechanisms targeting pruritic-specific neural pathways in NP.